At the molecular level, loss of PTEN in tumor cells leads to a significant downregulation of SHP‐2 (Src homology‐2‐containing protein tyrosine phosphatase 2), a negative regulator of the JAK/STAT3 pathway. This evidence concerns the gene PTEN and neoplasm.